In the expanded competing risk analysis of the MajesTEC-3 trial presented at IMS 2026, what was found when the components of progression-free survival were separated for teclistamab-daratumumab vs DARA-based triplets (DPd/DVd)?
The risk of progression was reduced by about 90%, with no difference in non-relapse mortality between arms (about 10% vs 8–9% at 3 years)
The risk of progression was reduced by about 50%, but non-relapse mortality was significantly higher with teclistamab-daratumumab
Progression rates were similar between arms, and the PFS benefit was driven mainly by lower non-relapse mortality with teclistamab-daratumumab